公开(公告)号：CA2414464A1

公开(公告)日：2002-01-10

申请号：CA2414464

申请日：2001-06-22

Applicant: ABBOTT LAB

Inventor： LINK JAMES T ,  SORENSEN BRYAN K

IPC: C07D295/04 ,  A61K31/198 ,  A61K31/397 ,  A61K31/4015 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/5375 ,  A61K31/5377 ,  A61P29/00 ,  A61P37/06 ,  C07C323/62 ,  C07D205/04 ,  C07D207/26 ,  C07D207/27 ,  C07D211/60 ,  C07D211/62 ,  C07D295/096 ,  C07D295/13 ,  C07D295/18 ,  C07D295/185 ,  C07D401/12 ,  A61K31/16 ,  A61K31/33 ,  C07D295/08 ,  C07D295/12

Abstract: The present invention relates to novel cyclopropane-containing diaryl sulfid e compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

公开(公告)号：AU2011202889A1

公开(公告)日：2011-07-07

申请号：AU2011202889

申请日：2011-06-16

Applicant: ABBOTT LAB

Inventor： WODKA DARIUSZ ,  LINK JAMES T ,  SHUAI QI ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J

IPC: C07D207/02 ,  C07C237/04 ,  C07C237/24 ,  C07D209/08 ,  C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta hydroxysteroid dehydrogenase Type I enzyme. The present invention further relates to the use of inhibitors of 11 -beta-hydroxysteroid dehydrogenase Type I enzyme for the io treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：CA2438480C

公开(公告)日：2011-05-03

申请号：CA2438480

申请日：2002-02-12

Applicant: ABBOTT LAB

Inventor： LINK JAMES T ,  SORENSEN BRYAN K ,  PATEL JYOTI R ,  ARENDSEN DAVID L ,  LI GAOQUAN

IPC: C07C311/08 ,  C07D317/32 ,  A61K31/11 ,  A61K31/136 ,  A61K31/18 ,  A61K31/197 ,  A61K31/223 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/381 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/427 ,  A61K31/445 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/00 ,  A61P3/04 ,  A61P3/10 ,  A61P5/46 ,  A61P9/12 ,  A61P11/02 ,  A61P11/06 ,  A61P19/02 ,  A61P37/06 ,  A61P37/08 ,  C07C307/04 ,  C07C307/10 ,  C07D207/08 ,  C07D207/16 ,  C07D207/27 ,  C07D211/60 ,  C07D265/32 ,  C07D277/20 ,  C07D277/34 ,  C07D295/092 ,  C07D307/20 ,  C07D307/33 ,  C07D309/36 ,  C07D333/32 ,  C07D403/04

Abstract: Compounds of formula (I) (I), or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.

公开(公告)号：NZ555971A

公开(公告)日：2011-01-28

申请号：NZ55597106

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  SHUAI QI ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YONG HONG ,  YEH VINCE S ,  KURUKULASURIYA RAVI

IPC: C07C233/63 ,  A61K31/165 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4409 ,  A61P3/04 ,  A61P3/10 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: Disclosed are adamantylaminocarbonyl compounds of formula (I), wherein the substituents are as defined in the specification, that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Also disclosed is the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：ZA200609946B

公开(公告)日：2008-06-25

申请号：ZA200609946

申请日：2006-11-28

Applicant: ABBOTT LAB

Inventor： LINK JAMES T ,  ROHDE JEFFREY J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  DARIUSZ WODKA ,  QI SHUAI

IPC: A61K20090101 ,  C07D20090101 ,  C07D205/04 ,  C07D211/06 ,  C07D211/46 ,  C07D213/74 ,  C07D295/15

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：MX2007008238A

公开(公告)日：2007-08-17

申请号：MX2007008238

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： YONG HONG ,  LINK JAMES T ,  ROHDE JEFFREY J ,  PATEL JYOTI R ,  SHUAI QI ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YEH VINCE S ,  WINN MARTIN

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

Abstract: La presente invencion se refiere a compuestos que son inhibidores de la enzima 11-beta hidroxiesteroide deshidrogenada tipo 1. La presente invencion ademas se refiere al uso de inhibidores de la enzima 11-beta hidroxiesteroide deshidrogenada tipo 1 para el tratamiento de la diabetes no dependiente de insulina tipo 2, resistencia a la insulina, obesidad, trastornos de lipidos, sindrome metabolico y otras enfermedades y condiciones que son mediadas por la accion excesiva del glucocorticoide.

公开(公告)号：CA2594116A1

公开(公告)日：2006-07-13

申请号：CA2594116

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： PATEL JYOTI R ,  DINGES JURGEN ,  ROHDE JEFFREY J ,  SHUAI QI ,  SORENSEN BRYAN K ,  LINK JAMES T ,  KURUKULASURIYA RAVI ,  YONG HONG ,  YEH VINCE S

IPC: C07C233/63 ,  A61K31/165 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4409 ,  A61P3/04 ,  A61P3/10 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：CA2594098A1

公开(公告)日：2006-07-13

申请号：CA2594098

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： SHUAI QI ,  ROHDE JEFFREY J ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：AU2006204017A1

公开(公告)日：2006-07-13

申请号：AU2006204017

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： SHUAI QI ,  LINK JAMES T ,  SORENSEN BRYAN K ,  YEH VINCE S ,  PATEL JYOTI R ,  WINN MARTIN ,  YONG HONG ,  ROHDE JEFFREY J ,  DINGES JURGEN

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：ES2387326T3

公开(公告)日：2012-09-20

申请号：ES07760236

申请日：2007-04-06

Applicant: ABBOTT LAB

Inventor： YEH VINCE S ,  KURUKULASSURIYA RAVI ,  MADAR DAVID J ,  LINK JAMES T

IPC: C07D207/26 ,  C07D401/12

Abstract: Un compuesto de fórmula (I)o una de sus sales farmacéuticamente aceptables, o una combinación de las mismas, donde:n es 1;R1 escada uno de los cuales está insustituido o sustituido independientemente con 1 o 2 sustituyentesseleccionados independientemente del grupo que consiste de alquilo, alquenilo, haloalquilo, Cl, Br, F, I, -CN,-NO2, -ORb, -SRb, -S(O)Rz, -S(O)2Rz, -NRaRb, -C(O)Rb, -C(O)ORb, -C(O)NRaRb, -S(O)2NRaRb, -C(>=NOH)NH2,-C(>=NH)NH2, -Rc, -(CRdRe)m-CN, -(CRdRe)m-ORb, -(CRdRe)m-SRb, -(CRdRe)m-S(O)2Rz, -(CRdRe)m-NRaRb,-(CRdRe)m-C(O)Rb, -(CRdRe)m-C(O)ORb, -(CRdRe)m-S(O)2NRaRb, -(CRdRe)m-Rc, -N(Ra)-(CRdRe)m-C(O)Rb,N(Ra)-(CRdRe)m-C(O)ORb, -N(Ra)-(CRdRe)m-C(O)NRaRb, -O-(CRdRe)m-C(O)Rb, -O-(CRdRe)m-C(O)ORb, y -O-(CRdRe)m-C(O)NRaRb;R2 y R3, en cada aparición, son cada uno independientemente hidrógeno o alquiloR4 es -(CH2)-O-G o -(CH2)-N(Re)-G, donde G, en cada aparición, es independientemente fenilo o piridinilo, ycada G está insustituido o sustituido independientemente con 1 o 2 sustituyentes seleccionadosindependientemente del grupo que consiste de alquilo, alquenilo, haloalquilo, Cl, Br, F, I, -CN, -NO2, -ORd,-S(Rd), -S(O)(alquilo), -S(O) (haloalquilo), -S(O)2(alquilo), -S(O)2(haloalquilo), -NRdRe, -C(O)(Rd), -C(O)ORd,-C(O)NRdRe, -S(O)2NRdRe, Rc, -(CRdRe)m-CN, -(CRdRe)m-NO2, -(CRdRe)m-ORd, -(CRdRe)m-S(Rd), -(CRdRe)m-S(O)(alquilo), -(CRdRe)m-S(O)(haloalquilo), -(CRdRe)m-S(O)2(alquilo), -(CRdRe)m-S(O)2(haloalquilo), -(CRdRe)m-NRdRe, -(CRdRe)m-C(O)(Rd), -(CRdRe)m-C(O)ORd, -(CRdRe)m-C(O)NRdRe, -(CRdRe)m-S(O)2NRdRe, y -(CRdRe)m-Rc;Ra, en cada aparición, es independientemente hidrógeno o alquilo;Rb, en cada aparición, es independientemente hidrógeno, alquilo, haloalquilo, Rc o -(CRdRe)m-Rc;Rz, en cada aparición, es independientemente alquilo, haloalquilo, Rc o -(CRdRe)m-Rc;Rc, en cada aparición, es heteroarilo donde heteroarilo es imidazolilo, triazolilo y tetrazolilo, donde cadaRc está insustituido o sustituido independientemente con 1 o 2 sustituyentes seleccionadosindependientemente del grupo que consiste de alquilo, alquenilo, haloalquilo, Cl, Br, F, I, -CN, -NO2, -ORd,-S(Rd), -S(O)(alquilo), -S(O)(haloalquilo), -S(O)2(alquilo), -S(O)2(haloalquilo), -NRdRe, -C(O)(Rd), -C(O)ORd,-C(O)NRdRe, -S(O)2NRdRe, -(CRdRe)m-CN, -(CRdRc)m-NO2, -(CRdRe)m-ORd, -(CRdRc)m-S(Rd), -(CRdRe)m-S(O)(alquilo), -(CRdRe)m-S(O)(haloalquilo), -(CRdRc)m-S(O)2(alquilo), -(CRdRe)m-S(O)2(haloalquilo), -(CRdRe)m-NRdRe, -(CRdRe)m-C(O)(Rd), -(CRdRe)m-C(O)ORd, -(CRdRe)m-C(O)NRdRe, y -(CRdRe)m-S(O)2NRdRe;Rd y Re, en cada aparición, son independientemente hidrógeno o alquilo C1-C6; y m es 1.